Brian Orelli, PhD

Lessons from the year give biotech investors clues on what to look for next year.

A battle of two platform drugmakers.

Seeming anything -- including preclinical data -- will spark shares of the beaten-down biotech.

Positive phase 2 data from the small biotech sends shares higher.

The biotech produces positive earnings, but to stay there it's going to have to get some more drugs approved.

After shedding its biologics division, the biodefense specialist waits for final details of its contract with the U.S. government to sell its anthrax vaccine.

Investors believe a Trump presidency is better for the biotech industry than a Clinton one would have been.

The biotech has enough cash to work out the problems with its gene therapy process.

Investors re-evaluate biotechs' valuations now that Hilary Clinton won't be president.

FDA uncertainty plagues the biotech's share price.

Investors are warming up to Celldex's newest acquisition.

The biotech's kidney cancer drug, Cabometyx, is off to a good start in its first full quarter on the market.

A solid third-quarter earnings report has the drugmaker's shares heading higher.

More positive phase 3 data for its SMA drug Spinraza sends shares of the biotech soaring.

Lopsided deaths in the biotech's clinical trial testing revusiran led to discontinuation of the drug's development, but investors need more data to be comfortable with the rest of the company's pipeline.

Third-quarter earnings were solid, but 2017 is setting up to be an inflection point for the drugmaker.

The biotech continues its solid launch of its kidney cancer drug Cabometyx.

The cancer-test maker reports solid third-quarter results on its way to breakeven.

The scientific-test maker registers a solid third quarter.

The biotech falls on data released ahead of next month's American Society of Hematology meeting.